Comité Exécutif: Lite Strategy, Inc.

Dirigeant
Fonctions occupéesDepuis
Justin File

Justin File

56 ans

Chief Executive Officer 01/08/2024
Director of Finance/CFO 01/08/2023
Corporate Secretary 01/08/2023

Composition du Conseil d'Administration: Lite Strategy, Inc.

Administrateur
ComitésDepuis
Fred Driscoll

Fred Driscoll

74 ans

Compensation Committee 07/04/2017
Audit Committee Chair 01/08/2024
Governance Committee
Nominating Committee
James Flynn

James Flynn

46 ans

Audit Committee 03/01/2024
Compensation Committee
Governance Committee 05/12/2024
Nominating Committee 05/12/2024
Compensation Committee Chair 05/12/2024
Charles Lee

Charles Lee

48 ans

Audit Committee
Compensation Committee
Governance Committee
Nominating Committee
Nick Glover

Nick Glover

57 ans

Audit Committee 11/06/2013
Compensation Committee Chair 20/06/2013
Joshua Riezman

Joshua Riezman

43 ans

Director/Board Member 05/08/2025
Justin File

Justin File

56 ans

Director/Board Member 14/11/2025

Anciens Dirigeants et Administrateurs: Lite Strategy, Inc.

Insider
Fonctions occupées
DepuisJusqu'au
Thomas Reynolds
Thomas Reynolds
Director/Board Member 11/02/2013 04/11/2025
Independent Dir/Board Member 11/02/2013 04/11/2025
Steven Wood
Steven Wood
Director/Board Member 31/10/2023 05/08/2025
Independent Dir/Board Member 31/10/2023 05/08/2025
Taheer Mehboob Datoo
Taheer Mehboob Datoo
Director/Board Member 31/10/2023 22/07/2025
Jason Sausser
Jason Sausser
Chief Tech/Sci/R&D Officer 01/03/2022 01/02/2025
Nicole Iida
Nicole Iida
General Counsel - 01/12/2024
Richard Ghalie
Richard Ghalie
Chief Tech/Sci/R&D Officer 01/03/2016 01/08/2024
David Urso
David Urso
Director/Board Member 08/06/2023 01/08/2024
Chief Executive Officer 02/06/2023 01/08/2024
Chief Operating Officer 16/07/2018 02/06/2023
General Counsel 07/03/2014 02/06/2023
President 02/06/2023 01/08/2024
Charles Baltic
Charles Baltic
Director/Board Member 20/10/2011 05/01/2023
Chairman 05/01/2023 01/08/2024
Independent Dir/Board Member 20/10/2011 01/08/2024
Sujay Kango
Sujay Kango
Director/Board Member 22/11/2021 31/10/2023
Independent Dir/Board Member 22/11/2021 31/10/2023
Daniel Gold
Daniel Gold
Director/Board Member 23/04/2010 31/10/2023
Chief Executive Officer 27/04/2010 15/04/2011
President 27/04/2010 02/06/2023
Tamar Howson
Tamar Howson
Director/Board Member 01/07/2019 31/10/2023
Independent Dir/Board Member 01/07/2019 31/10/2023
Brian Drazba
Brian Drazba
Comptroller/Controller/Auditor 03/04/2017 -
Director of Finance/CFO 03/04/2017 01/08/2023
Corporate Secretary 03/04/2017 01/08/2023
Alejandro Ricart
Alejandro Ricart
Corporate Officer/Principal 07/02/2022 01/06/2023
Tina Beamon
Tina Beamon
Compliance Officer 01/06/2021 01/04/2023
Christine Anna White
Christine Anna White
Director/Board Member 10/08/2010 01/12/2015
Chairman 01/12/2015 05/01/2023
Independent Dir/Board Member 01/12/2015 05/01/2023
Eric Deng
Eric Deng
Chief Tech/Sci/R&D Officer 01/10/2021 01/01/2023
Cheryl Cohen
Cheryl Cohen
Director/Board Member 10/04/2020 06/12/2022
Independent Dir/Board Member 10/04/2020 06/12/2022
Benjamin Cadieux
Benjamin Cadieux
Chief Tech/Sci/R&D Officer 01/03/2021 01/12/2022
Ofir Moreno
Ofir Moreno
Chief Tech/Sci/R&D Officer 01/07/2012 01/07/2019
Corporate Officer/Principal 01/07/2019 01/07/2022
Anne Frese
Anne Frese
Human Resources Officer 22/06/2022 -
Jamie A. Tereschuck
Jamie A. Tereschuck
Human Resources Officer - 01/03/2022
Caroline Ruiz
Caroline Ruiz
Chief Tech/Sci/R&D Officer 01/01/2022 -
Kevan E. Clemens
Kevan E. Clemens
Director/Board Member 03/12/2014 22/11/2021
Independent Dir/Board Member 03/12/2014 22/11/2021
Eugene Park
Eugene Park
Corporate Officer/Principal - -
Sales & Marketing 01/07/2021 -
Igor Gorbatchevsky
Igor Gorbatchevsky
Corporate Officer/Principal 01/04/2019 01/06/2021
Robert D. Mass
Robert D. Mass
Chief Tech/Sci/R&D Officer 01/06/2011 03/05/2021
David Walsey
David Walsey
Investor Relations Contact 01/02/2018 01/05/2021
Public Communications Contact 01/02/2018 01/05/2021
Brian Powl
Brian Powl
Sales & Marketing 15/09/2020 -
Thomas M. Zech
Thomas M. Zech
Comptroller/Controller/Auditor 21/10/2011 13/03/2012
Director of Finance/CFO 18/06/2010 03/04/2017
Corporate Secretary 21/10/2011 03/04/2017
Pete de Spain
Pete de Spain
Investor Relations Contact 15/04/2011 01/01/2017
Public Communications Contact - 01/01/2017
Todd Butler
Todd Butler
Corporate Officer/Principal 01/01/2015 01/01/2017
Leah Cann
Leah Cann
Director/Board Member 01/03/2009 01/09/2016
Independent Dir/Board Member 01/03/2009 01/09/2016
Karen Potts
Karen Potts
General Counsel 01/10/2014 -
Wendy J. Levin
Wendy J. Levin
Corporate Officer/Principal 01/08/2013 -
Kelly Powell
Kelly Powell
Corporate Officer/Principal 01/05/2013 -
Bryan Williams
Bryan Williams
Chairman 24/11/2006 27/01/2013
Independent Dir/Board Member 01/03/2006 27/01/2013
Philip A. Johnston
Philip A. Johnston
Director/Board Member 01/04/2001 13/04/2011
Paul John Nestel
Paul John Nestel
Director/Board Member 01/04/2001 08/08/2010
Christopher Naughton
Christopher Naughton
President 01/12/2000 01/12/2009
Stephen Breckenridge
Stephen Breckenridge
Director/Board Member - 15/12/2008
William Dodge Rueckert
William Dodge Rueckert
Director/Board Member 01/03/2012 -
Chief Executive Officer 01/01/2010 24/07/2012
Chairman 01/01/2010 24/07/2012
Independent Dir/Board Member 01/01/2007 -
Graham Kelly
Graham Kelly
Director/Board Member 01/04/2001 01/01/2006
Chairman - -
Founder 01/04/2001 01/01/2006
Alan J. Husband
Alan J. Husband
Chief Tech/Sci/R&D Officer 16/10/2009 -
David Sheon
David Sheon
Public Communications Contact - -
David R. Seaton
David R. Seaton
Director of Finance/CFO - 21/06/2010
President 03/12/2009 27/04/2010
Corporate Secretary - -

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme6
Femme0

Dont comité exécutif

Homme1
Femme0

Dont Administrateurs

Homme6
Femme0
Logo Lite Strategy, Inc.
Lite Strategy, Inc., anciennement MEI Pharma, Inc., est une société de gestion de trésorerie spécialisée dans le Litecoin. La société accumule des LTC purs grâce à une gestion active de sa trésorerie et concentre ses avoirs par action, ce qu’elle considère comme l’indicateur ultime de la valeur pour les actionnaires. Il s’agit d’une société pharmaceutique au stade clinique qui se consacre au développement de traitements anticancéreux différenciés visant à améliorer les résultats pour les patients. Son approche en matière de développement de médicaments oncologiques consiste à évaluer ses candidats-médicaments en association avec les traitements de référence afin de surmonter les mécanismes de résistance connus et de répondre à des besoins médicaux clairement identifiés. Le portefeuille de candidats-médicaments comprend le voruciclib, un inhibiteur oral de la kinase 9 dépendante des cyclines (CDK9), et le zandelisib, un inhibiteur sélectif de la PI3Kd administré par voie orale une fois par jour. Le voruciclib est un inhibiteur sélectif de la CDK9 administré par voie orale qui présente un potentiel pour le traitement à la fois des hémopathies malignes et des tumeurs solides. Le voruciclib, un inhibiteur sélectif de la CDK9 administré par voie orale, fait actuellement l'objet d'un développement clinique pour le traitement de la leucémie myéloïde aiguë.
Employés
4

Départs de Personnes Clées

David Urso
-
David Urso

Chief Executive Officer

02/06/2023 01/08/2024

Charles Baltic
-
Charles Baltic

Chairman

05/01/2023 01/08/2024

Daniel Gold
-
Daniel Gold

Chief Executive Officer

27/04/2010 15/04/2011

Christine Anna White
-
Christine Anna White

Chairman

01/12/2015 05/01/2023

Bryan Williams
-
Bryan Williams

Chairman

24/11/2006 27/01/2013

William Dodge Rueckert
-
William Dodge Rueckert

Chief Executive Officer

01/01/2010 24/07/2012